Yu X F, Yang C, Liang L H, Liu B, Zhou B, Li B, Han Z C
State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Leukemia. 2006 Jan;20(1):1-8. doi: 10.1038/sj.leu.2404021.
Considerable studies have demonstrated the pivotal roles of matrix metalloproteinases (MMPs) in leukemia dissemination and extramedullary infiltration. Tissue inhibitors of matrix metalloproteinases (TIMPs) are multifunctional proteins with MMPs inhibitory effects. However, little is known about the application of TIMPs in the treatment of leukemia. Here, we investigated the effects of TIMP-3 overexpression via adenoviral gene delivery on the in vitro growth and invasiveness of leukemic cells and the in vivo progress of K562-derived xenografts in nude mice. The in vitro invasiveness of K562 cells was markedly impaired by AdTIMP-3 infection. Moreover, TIMP-3 significantly inhibited K562-derived angiogenic factors-induced proliferation, migration and bFGF-induced tube formation of endothelial cells (ECs) in vitro, and reduced VEGF-induced gelatinases expression and activation in ECs. Although TIMP-3 overexpression had no direct effect on the growth of K562 cells in vitro, repeated intratumoral injection of AdTIMP-3 significantly inhibited the growth of K562 xenografts in nude mice. Furthermore, lower microvessel density, less vessel maturity and increased apoptosis were observed in AdTIMP-3-treated K562 xenografts, suggesting the importance of antiangiogenic action of TIMP-3. These data demonstrated the potential of applying AdTIMP-3 as an effective antiangiogenic adjuvant in the treatment of leukemia progression.
大量研究表明基质金属蛋白酶(MMPs)在白血病扩散和髓外浸润中起关键作用。基质金属蛋白酶组织抑制剂(TIMPs)是具有MMPs抑制作用的多功能蛋白。然而,关于TIMPs在白血病治疗中的应用知之甚少。在此,我们通过腺病毒基因递送研究了TIMP-3过表达对白血病细胞体外生长和侵袭性以及裸鼠体内K562来源异种移植瘤进展的影响。AdTIMP-3感染显著损害了K562细胞的体外侵袭性。此外,TIMP-3在体外显著抑制K562来源的血管生成因子诱导的内皮细胞(ECs)增殖、迁移以及bFGF诱导的ECs管形成,并降低VEGF诱导的ECs中明胶酶的表达和激活。虽然TIMP-3过表达对K562细胞的体外生长没有直接影响,但瘤内重复注射AdTIMP-3显著抑制了裸鼠体内K562异种移植瘤的生长。此外,在AdTIMP-3处理的K562异种移植瘤中观察到微血管密度降低、血管成熟度降低和细胞凋亡增加,提示TIMP-3抗血管生成作用的重要性。这些数据证明了应用AdTIMP-3作为治疗白血病进展的有效抗血管生成佐剂的潜力。